Revenue Recognition and Accounts Receivable - Additional Information (Detail) € in Millions	1 Months Ended		12 Months Ended
	Mar. 31, 2022	Apr. 30, 2021	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 USD ($)
Revenue Recognition And Accounts Receivable [Line Items]
Marketing service fees			$ 53,296,000		$ 55,276,000		$ 54,925,000
Cost of sales			260,368,000		123,544,000		114,914,000
Addition resulting from the Merger with SeaSpine			137,000
Sale of receivables			10,000,000	€ 9.2	9,600,000	€ 9.2	9,900,000	€ 8.4
Related fees recorded as interest expense			400,000		300,000		200,000
CARES Act of 2020 funds received					(4,791,000)		(9,060,000)		$ 13,900,000
Medicare recoupment	0.50	0.25
Contract liability, total							4,791,000
Other Asset Impairment Charges			400,000
Other Contract Assets [Member]
Revenue Recognition And Accounts Receivable [Line Items]
Other contract assets impairment					0
Other Long-Term Assets [Member]
Revenue Recognition And Accounts Receivable [Line Items]
Other contract assets			300,000		1,100,000
Shipping and Handling Costs [Member]
Revenue Recognition And Accounts Receivable [Line Items]
Cost of sales			9,500,000		$ 4,200,000		$ 3,500,000
Biologics [Member]
Revenue Recognition And Accounts Receivable [Line Items]
Marketing service fees			$ 53,300,000
Marketing service fee as percentage of segment revenues			32.00%	32.00%